EDIT Should I Buy

EDIT is not a good buy right now for a Beginner, long-term investor with $50k–$100k who is unwilling to wait for better entry points. The stock is highly speculative (very high volatility, loss-making biotech), there are no proprietary buy signals today, and the near-term price action is weak/indecisive. Options positioning is very bullish (call-heavy), but without a clear catalyst in the past week and with ongoing losses, the risk/reward is not attractive for a long-term beginner at this moment.

Trend/price action: Regular session was down (-2.37%) with a small post-market uptick (+0.49%). Moving averages are converging, which typically signals a market waiting for direction rather than a confirmed uptrend. Momentum: MACD histogram is slightly positive (0.0144) but contracting, suggesting upside momentum is fading rather than accelerating. RSI(6) at ~43.8 is neutral-to-soft (not oversold), so there is no strong rebound setup. Key levels: Pivot ~2.159. Nearest support S1 ~1.964 (then S2 ~1.844). Resistance R1 ~2.353 (then R2 ~2.473). With price ~2.06, the stock sits below pivot and closer to support than resistance—technically not an attractive “buy-now” location for an impatient investor. Pattern-based short-term odds: The provided pattern study implies a modest negative expected move next day (40% chance to -0.94%) and only small positive drift over 1 week/month. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.